This company has been acquired
VAPO Stock Overview
A medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Vapotherm, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.17 |
| 52 Week High | US$3.44 |
| 52 Week Low | US$0.70 |
| Beta | -1.1 |
| 11 Month Change | 0.59% |
| 3 Month Change | 2.60% |
| 1 Year Change | -22.22% |
| 33 Year Change | -98.97% |
| 5 Year Change | -97.04% |
| Change since IPO | -98.30% |
Recent News & Updates
Recent updates
Vapotherm announces $23M private placement
Feb 08Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M
Nov 02Vapotherm draws downgrade at William Blair after 2Q results
Aug 04Vapotherm: Out Of Air
May 11Is Vapotherm (NYSE:VAPO) Using Too Much Debt?
Jan 24
Vapotherm: Hardly Breathing Room
Jul 11Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?
May 10Vapotherm reports Q1 results
May 05The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares
Mar 12Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year
Mar 11Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?
Jan 19
Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth
Jan 13Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares
Dec 14Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%
Dec 11Vapotherm shares +9% on higher Q4 guidance
Dec 01Vapotherm: The Game Has Completely Changed
Nov 13Shareholder Returns
| VAPO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.2% | 2.0% |
| 1Y | -22.2% | 22.6% | 32.4% |
Return vs Industry: VAPO underperformed the US Medical Equipment industry which returned 18.6% over the past year.
Return vs Market: VAPO underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| VAPO volatility | |
|---|---|
| VAPO Average Weekly Movement | 1.7% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VAPO's share price has been volatile over the past 3 months.
Volatility Over Time: VAPO's weekly volatility has decreased from 27% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 182 | Joe Army | www.vapotherm.com |
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation.
Vapotherm, Inc. Fundamentals Summary
| VAPO fundamental statistics | |
|---|---|
| Market cap | US$13.61m |
| Earnings (TTM) | -US$54.42m |
| Revenue (TTM) | US$70.92m |
0.2x
P/S Ratio-0.2x
P/E RatioIs VAPO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAPO income statement (TTM) | |
|---|---|
| Revenue | US$70.92m |
| Cost of Revenue | US$37.71m |
| Gross Profit | US$33.21m |
| Other Expenses | US$87.63m |
| Earnings | -US$54.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.71 |
| Gross Margin | 46.82% |
| Net Profit Margin | -76.74% |
| Debt/Equity Ratio | -145.6% |
How did VAPO perform over the long term?
See historical performance and comparison